ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
네비보롤정 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.5%로 15억 7,000만 달러로 성장합니다. 예측 기간 중의 성장은 1인당 의료비 지출 증가, 심혈관 위험을 증가시키는 좌식 생활습관 증가, 식습관 및 스트레스 관련 요인과 관련된 도시화 확대, 당뇨병과 같은 동반 질환의 유병률 증가, 공공 심혈관 건강 캠페인에 대한 투자 증가에 기인합니다. 예측 기간 중 첨단 포장 동향으로는 약물전달 기술의 지속적인 혁신, 서방형 제제 개발, 복약 순응도 강화을 위한 디지털 헬스 플랫폼의 통합 확대, 제조 효율성 및 품질관리의 발전, 지속가능한 의약품 포장에 대한 강조 등이 있습니다.
심혈관 질환의 유병률 증가는 향후 네비보롤 정제 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환은 심장과 혈관에 영향을 미치는 다양한 장애를 포함하며, 종종 심장마비나 뇌졸중과 같은 심각한 증상을 유발하는 혈류 제한을 동반합니다. 심혈관 질환 증가는 신체 활동을 줄이고 비만, 고혈압, 심장 기능 저하와 같은 문제의 위험을 증가시키는 좌식 생활 방식과 관련이 있습니다. 네비보롤정은 선택적 베타1 수용체 차단으로 혈압을 낮추고, 산화질소를 통한 혈관 확장을 촉진하여 혈류를 개선하고 심장의 업무량을 감소시켜 심혈관 질환 예방에 도움을 줍니다. 예를 들어 2024년 12월 호주의 국가 기관인 호주 보건 복지 연구소는 2022-23년 호주에서 심혈관 질환과 관련된 응급 진료가 33만 1,400건(인구 10만 명당 1,300건)이 발생했다고 보고했습니다. 이 중 소생술이 필요한 경우는 5.2%, 응급 44%, 긴급 37%, 준응급 12%, 비응급 1.4%였습니다. 이처럼 심혈관 질환의 유병률 증가는 네비보롤 정제 시장의 성장을 가속하고 있습니다.
제네릭 의약품에 대한 수요 증가는 네비보롤 정제 시장의 성장을 더욱 촉진할 것으로 예측됩니다. 제네릭 의약품은 오리지널 의약품과 동일한 유효성분, 용법, 용량, 강도, 투여경로를 포함한 의약품이지만, 오리지널 의약품의 특허가 만료되면 화학명으로 판매되는 의약품을 말합니다. 제네릭 의약품에 대한 선호도가 높아지는 배경에는 오리지널 의약품과 동일한 치료 효과를 더 낮은 비용으로 제공하고 접근성을 높인다는 제네릭 의약품의 경제성이 있습니다. 네비보롤 정은 고혈압 및 심장병 치료에 있으며, 오리지널 의약품을 대체할 수 있는 비용 효율적인 치료제를 제공함으로써 이러한 추세에 기여하고 있습니다. 예를 들어 2024년 9월, 미국 산업협회인 AAM(Association for Accessible Medicines)은 2023년 바이오시밀러로 인한 절감액이 2023년에는 30% 이상 증가하며 124억 달러에 달하며, 제네릭 의약품과 바이오시밀러에 의한 절약액 합계는 2022년 4,080억 달러에서 4,450억 달러로 증가하며, 370억 달러의 증가를 반영했다고 보고했습니다. 따라서 제네릭 의약품에 대한 수요 증가는 네비보롤 정제 시장 확대에 박차를 가하고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 네비보롤정 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 네비보롤정 시장 : 성장률 분석
세계의 네비보롤정 시장 실적 : 규모와 성장, 2019-2024
세계의 네비보롤정 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 네비보롤정 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 네비보롤정 시장 : 제형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
즉방정
서방정
세계의 네비보롤정 시장 : 강도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
2.5mg정
5mg정
10mg정
세계의 네비보롤정 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 네비보롤정 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
고혈압
심부전
기타 용도
세계의 네비보롤정 시장 : 서브 세분화, 즉방성 정제(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
필름 코팅정
비코팅정
분산정
구강내 붕괴정
당의정
세계의 네비보롤정 시장 : 서브 세분화, 서방정(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
서방형 매트릭스정
지연 방출정
서방정
2층정
서방형 침투압정
제7장 지역별·국가별 분석
세계의 네비보롤정 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 네비보롤정 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
네비보롤정 시장 : 경쟁 구도
네비보롤정 시장 : 기업 개요
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Macleods Pharmaceuticals Ltd.
Menarini Group
Aurobindo Pharma
Cipla Inc.
Lupin Limited
Zydus Group
Ranbaxy Laboratories Ltd.
Glenmark Pharmaceuticals
Alkem Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Zhejiang Huahai Pharmaceutical Co. Ltd.
Aristo Pharmaceuticals Pvt. Ltd.
Fuan Pharmaceutical Group Co. Ltd.
ANI Pharmaceuticals Inc.
Camber Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
네비보롤정 시장 2029 : 새로운 기회를 제공하는 국가
네비보롤정 시장 2029 : 새로운 기회를 제공하는 부문
네비보롤정 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Nebivolol tablets are oral medications primarily used to treat high blood pressure by blocking beta-adrenergic receptors, which helps reduce heart rate and relax blood vessels. They are also prescribed in certain cases of heart failure to enhance heart function and alleviate symptoms.
The main dosage forms of nebivolol tablets include immediate-release tablets and extended-release tablets. Immediate-release nebivolol tablets are oral formulations designed to quickly dissolve and release nebivolol into the bloodstream for rapid antihypertensive effect. These tablets come in various strengths, such as 2.5 mg, 5 mg, and 10 mg, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and more. They are used to treat conditions like hypertension, heart failure, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The nebivolol tablets market research report is one of a series of new reports from The Business Research Company that provides nebivolol tablets market statistics, including nebivolol tablets industry global market size, regional shares, competitors with a nebivolol tablets market share, detailed nebivolol tablets market segments, market trends and opportunities, and any further data you may need to thrive in the nebivolol tablets industry. This nebivolol tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nebivolol tablets market size has grown strongly in recent years. It will grow from $1.14 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to the increasing global prevalence of hypertension, growing awareness of cardiovascular health, an expanding aging population vulnerable to heart conditions, the development of healthcare infrastructure in emerging regions, and rising diagnosis rates of heart failure.
The nebivolol tablets market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth during the forecast period can be attributed to rising healthcare expenditure per capita, increasing adoption of sedentary lifestyles that elevate cardiovascular risks, expanding urbanization linked to dietary and stress-related factors, a growing prevalence of comorbid conditions such as diabetes, and increased investment in public cardiovascular health campaigns. Major trends in the forecast period include continuous innovations in drug delivery technologies, development of extended-release formulations, greater integration of digital health platforms to improve medication adherence, advancements in manufacturing efficiency and quality control, and a stronger focus on sustainable pharmaceutical packaging.
The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the nebivolol tablets market in the future. Cardiovascular diseases encompass a variety of disorders affecting the heart and blood vessels, often involving restricted blood flow that can result in serious conditions such as heart attacks or strokes. The increase in cardiovascular diseases is linked to sedentary lifestyles, which reduce physical activity and elevate the risk of issues like obesity, high blood pressure, and compromised heart function. Nebivolol tablets help prevent cardiovascular diseases by lowering blood pressure through selective beta-1 receptor blockade and promoting nitric oxide-mediated vasodilation, which improves blood flow and reduces the heart's workload. For example, in December 2024, the Australian Institute of Health and Welfare, a national agency in Australia, reported that Australia had 331,400 cardiovascular disease-related emergency visits (1,300 per 100,000 people) during 2022-23. Of these visits, 5.2% required resuscitation, 44% were emergencies, 37% were urgent, 12% were semi-urgent, and 1.4% were non-urgent. Thus, the growing prevalence of cardiovascular diseases is propelling the growth of the nebivolol tablets market.
The increasing demand for generic drugs is expected to further drive the growth of the nebivolol tablets market. Generic drugs are pharmaceutical products that contain the same active ingredients, dosage, strength, and route of administration as brand-name drugs but are marketed under their chemical names once the original drug's patent expires. The rising preference for generic drugs is fueled by their affordability, offering the same therapeutic benefits as branded drugs at significantly lower costs, thereby enhancing accessibility. Nebivolol tablets contribute to this trend by providing a cost-effective and therapeutically equivalent alternative to brand-name treatments for hypertension and heart conditions. For instance, in September 2024, the Association for Accessible Medicines (AAM), a US-based trade association, reported that savings from biosimilars increased by over 30% to $12.4 billion in 2023, while total savings from generics and biosimilars rose to $445 billion from $408 billion in 2022, reflecting a $37 billion increase. Therefore, the rising demand for generic drugs is fueling the expansion of the nebivolol tablets market.
Leading companies in the nebivolol tablets market are focusing on launching innovative products like generic antihypertensive tablets to improve access to essential hypertension treatments through affordable alternatives. Generic antihypertensive tablets are non-branded formulations that provide the same active ingredients, dosage, safety, and efficacy as their branded equivalents to manage high blood pressure. For example, in May 2024, Apnar Pharma LP, a US-based pharmaceutical firm, launched a generic version of Bystolic (Nebivolol Hydrochloride Tablets). This product was introduced in all four available strengths-2.5 milligrams, 5 milligrams, 10 milligrams, and 20 milligrams offering a comprehensive range of dosing options for healthcare providers and patients. This launch represents the company's strategic entry into the US antihypertensive market and helps expand access to a vital cardiovascular medication.
Major players in the nebivolol tablets market are AbbVie Inc., Abbott Laboratories Inc., Eli Lilly and Company, Viatris Inc., Sandoz International GmbH, Macleods Pharmaceuticals Ltd., Menarini Group, Aurobindo Pharma, Cipla Inc., Lupin Limited, Zydus Group, Ranbaxy Laboratories Ltd., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Aristo Pharmaceuticals Pvt. Ltd., Fuan Pharmaceutical Group Co. Ltd., ANI Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Octavius Pharma.
North America was the largest region in the nebivolol tablets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nebivolol tablets report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nebivolol tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nebivolol tablets market consists of sales of geriatric-specific nebivolol, pediatric trial formulations, and nebivolol APIs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nebivolol Tablets Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nebivolol tablets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nebivolol tablets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nebivolol tablets market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Nebivolol Tablets Market Characteristics
3. Nebivolol Tablets Market Trends And Strategies
4. Nebivolol Tablets Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Nebivolol Tablets Growth Analysis And Strategic Analysis Framework
5.1. Global Nebivolol Tablets PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nebivolol Tablets Market Growth Rate Analysis
5.4. Global Nebivolol Tablets Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nebivolol Tablets Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nebivolol Tablets Total Addressable Market (TAM)
6. Nebivolol Tablets Market Segmentation
6.1. Global Nebivolol Tablets Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate Release Tablets
Extended Release Tablets
6.2. Global Nebivolol Tablets Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
2.5 Mg Tablets
5 Mg Tablets
10 Mg Tablets
6.3. Global Nebivolol Tablets Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Nebivolol Tablets Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypertension
Heart Failure
Other Applications
6.5. Global Nebivolol Tablets Market, Sub-Segmentation Of Immediate Release Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Film-Coated Tablets
Uncoated Tablets
Dispersible Tablets
Orally Disintegrating Tablets
Sugar-Coated Tablets
6.6. Global Nebivolol Tablets Market, Sub-Segmentation Of Extended Release Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Modified-Release Matrix Tablets
Delayed-Release Tablets
Controlled-Release Tablets
Dual-Layer Tablets
Extended-Release Osmotic Tablets
7. Nebivolol Tablets Market Regional And Country Analysis
7.1. Global Nebivolol Tablets Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nebivolol Tablets Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
